Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors

N/ACompletedNCT06119347

First Affiliated Hospital of Wenzhou Medical University1,581 enrolled

Overview

The goal of this a retrospective real-world study is to compare the AKI events in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody (AntiVEGF) vs immune checkpoint inhibitors (ICIs). The main question it aims to answer is whether the choice between AntiVEGF and ICIs affects the risks of acute kidney injury in cancer patients. Cancer patients receiving AntiVEGF will be compared to those treated with ICIs to see if the AKI incidence is higher in patients receiving ICIs.

Study Type

OBSERVATIONAL

Enrollment

1,581

Conditions

AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs

Interventions

AntiVEGFDRUG

anti-vascular endothelial growth factor monoclonal antibody drug includes bevacizumab;

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \>=20yr; * Patients must have at least one "Evaluation and Management"visit with a diagnosis of cancer within 12 months before index date (In situ biopsy will not be required, since patients may receive a diagnosis from a biopsy of metastatic site); * Indication to initiate AntiVEGF or ICIs Exclusion Criteria: * Patients without valid data and less than 3 months followup; * Patients without baseline Scr value within 12 mon before index date; * Patients with combination therapy of Anti-VEGF and ICIs ; * Patients with chronic renal failure

Outcomes

Primary Outcomes

accumulative incidence of sustained AKI

sustained AKI will be defined as the elevation ≥1.5 times baseline sCr for ≥72hours according to the Kidney Disease Improving Global Outcomes (KDIGO) sCr criteria

Time frame: 12 months after index date